Oxaprozin

• Catalog No.: DB00991
• CAS Number: 21256-18-8
• M. F.: C18H15NO3
• M. W.: 293.3166

SYNONYMS

• IUPAC name: 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
• IUPAC Traditional name: oxaprozin
• Brand Name: Daypro; Voir; Alvo; Daypro Alta; Deflam
• Synonyms: Oxaprozina [INN-Spanish]; Oxaprozinum [INN-Latin]; Oxaprozine [INN-French]

DATABASE IDS

• PubChem CID: 4614
• PubChem SID: 46506429
• CAS Number: 21256-18-8

PROPERTIES

• Hydrophobicity(logP): 3.7
• Solubility: Insoluble

DETAILS

Description (English)

• Drug Groups: approved
• Description: Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
• Indication: Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
• Pharmacology: Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
• Toxicity: Oral, mouse: LD₅₀ = 1210 mg/kg; Oral, rabbit: LD₅₀ = 172 mg/kg; Oral, rat: LD₅₀ = 4470 mg/kg
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.
• Absorption: Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
• Half Life: 54.9 hours
• Protein Binding: >99.5% bound to albumin
• Elimination: Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite.; Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
• Distribution: * 11 to 17 L/70 kg
• References: Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. [Pubmed] ; Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

REFERENCES

• Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. PubmedZhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. Pubmed